drugset / Trial / NCT04235296

Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound

NCT04235296

Phase 1 Unknown 30 enrolled Chinese PLA General Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Treatment of extensive deep burn residual wounds is a common problem in burn plastic surgery. Due to bacterial invasion, excessive maturation of granulation tissue, poor abrasion resistance of new epithelium, and coexistence of wound healing and dissolution can lead to delayed wound healing. Residual wounds rarely heal spontaneously and are prone to recurrence. Mesenchymal stem cells (MSC) boost tissue repair through paracrine. Many biological effectors, including IGF-1, vascular endothelial growth factor (VEGF), TGF-β1 have been found in MSC conditioned media (MSC-CM), and play a role in promoting tissue repair and regeneration.Our previous animal experiments have confirmed the role of MSC-CM in regulating wound inflammation, repairing damaged repair cells and promoting wound regeneration. In here, we will evaluate the safety and effectiveness of mesenchymal stem cell conditioned medium-derived pleiotropic factor in treating residual burn wound.

Timeline

Start
2019-11-17
Primary completion
2020-12-30
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator NEPIDERMIN Protein / enzyme biologic
Subject mesenchymal stem cell conditioned medium-derived pleiotropic factor Unknown

Indications

No indication recorded.